Atea Pharmaceuticals, Inc.
AVIR· Nasdaq
Released Aug 12, 2026, after the close
10-Q filed Aug 12, 2026, 43 days after period end · 0001193125-26-347021
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$32.93M | -$37.16M | -$40.52M | -$28.18M |
| EPS Diluted | -$0.41 | -$0.44 | -$0.48 | -$0.34 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Atea Pharmaceuticals, Inc. · CIK 1593899 · Engraved from SEC EDGAR